The augment effects of magnesium hydride on the lipid lowering effect of atorvastatin: an in vivo and in vitro investigation.
Chen W, Zhang Y, Miao G, Ying Y, Ren Z, Sun X, Cai J, Shen H, Lu H. · Medical Gas Research. 2025;15:47.
What kind of evidence is this?
Preclinical
Controlled mouse and cell study
Metabolic and lipid health
Other forms
Mixed positive preclinical signal.
Animal tissue and biomarker outcomes plus cell-culture outcomes.
Methods at a glance
Male C57BL/6 mice on normal or high-fat diets and AML12 liver cells.
52 mice across experiments: 20 in a two-group study and 32 randomized to four groups of 8.
Up to 16 weeks in the animal experiments.
Diet containing 0.5 g/kg magnesium hydride, alone or with atorvastatin; corresponding cell experiments used magnesium-hydride exposure.
Hydrogen generated by magnesium hydride; not Brown's gas.
The intervention combines magnesium hydride chemistry with hydrogen generation; a tissue H2 dose was not isolated.
Not applicable — dietary and cell-culture exposure.
No oxygen was co-delivered.
Normal diet, high-fat diet and atorvastatin-only comparators.
Outcomes and reported result
Serum and hepatic lipids, liver histology, cellular lipid accumulation and signaling markers.
Magnesium hydride, including in combination with atorvastatin, improved several lipid and cellular endpoints; some comparisons were null.
The full article, animal and cell methods, figures and null findings were checked.
A reported association, difference or mechanism is not automatically a clinical benefit. Null findings, outcome type, study design and precision all matter.
Cautions and applicability
Preclinical evidence. Magnesium-related effects and hydrogen generation are not fully separable.
The reported high-fat-diet mouse and AML12 cell models.
SYRCLE animal-study tool — preliminary
Some concerns
Animal randomization was reported for part of the work, but concealment and assessor blinding were unclear.
Randomization/allocation reporting is limited · Blinding of personnel is unclear · Attrition is incompletely reported in places · Blinding of outcome assessors is unclear · No prospectively registered analysis plan identified
No single-study GRADE certainty rating is assigned. Certainty is assessed by important outcome across a complete eligible evidence set, not by attaching a final grade to one source.
Sources and record status
PMID: 39436189 · DOI: 10.4103/mgr.medgasres-d-23-00047
Free full article in PubMed Central.
PubMed record and PubMed Central full text; extraction checked 9 August 2026.
2026-08-10